Based on significant efficacy data and a well-tolerated side-effect profile, PDE-5 inhibitors are frequently used both as first-line outpatient therapy for PAH and acutely in critically ill patients. The gene discussed is PDE5A; the disease is pulmonary arterial hypertension.